Can IgA Nephropathy Cause Blood or Protein with Normal eGFR?
At a Glance
Yes. IgA nephropathy can cause persistent blood or protein in the urine while eGFR remains normal because kidney filters may be inflamed before overall filtering declines. Urine protein, blood pressure, biopsy findings, and eGFR trends help guide risk and monitoring.
In this answer
3 sections
Yes, you can absolutely have IgA nephropathy even if your eGFR (estimated glomerular filtration rate) is completely normal. However, persistent blood or protein in the urine can occur with many conditions—including infections, kidney stones, or other glomerular diseases—so IgA nephropathy is generally confirmed by a kidney biopsy [1]. A normal eGFR means your kidneys are still effectively filtering waste from your blood, but the presence of blood or protein indicates that the filters themselves are inflamed or injured [2][3].
Why Does Urine Show Damage if the eGFR is Normal?
IgA nephropathy begins when abnormal IgA proteins clump together and form immune complexes [4]. These complexes get trapped in the mesangium (the supporting tissue between the kidney’s capillary loops, within the filtering units called glomeruli) [2]. This triggers an inflammatory response and activates the complement system, a part of your body’s immune defense [5]. This inflammation causes changes that increase the permeability of the delicate filtration barrier, essentially creating “leaks” [2][4].
Red blood cells and protein leak through these more permeable barriers into your urine, causing hematuria (blood in the urine) and proteinuria (protein in the urine) [2][3]. At this stage, your kidneys compensate well. Because you have millions of these filters, a large number can be inflamed before the overall filtration capacity starts to measurably drop [1]. A normal eGFR is an encouraging sign, but it does not mean the condition is completely inactive.
Why Regular Monitoring Remains Crucial
Even with a normal eGFR, regular monitoring helps your care team understand your long-term risk and determine if treatment is needed. Treatment decisions—such as starting kidney-protective medications like ACE inhibitors or ARBs—are based on your overall risk, blood pressure, and protein levels, not just waiting for your eGFR to fall [6].
Tracking Proteinuria (Protein in Urine)
The amount of protein in your urine is one of the strongest predictors of long-term kidney health in IgA nephropathy [7]. Doctors often look at your time-averaged proteinuria (the average across multiple tests over time) using tests like a 24-hour collection or a spot urine protein-to-creatinine ratio (UPCR) or albumin-to-creatinine ratio (UACR). Having a time-averaged urine protein level above 0.5 grams per day is associated with a faster decline in kidney function [8][9]. Current guidelines often aim to reduce proteinuria as much as possible, sometimes targeting less than 0.3 grams per day, though this is an individualized goal rather than a universal guarantee [10].
Watching Hematuria Trends
Microscopic blood in the urine often fluctuates. Persistent or worsening microscopic hematuria is associated with a higher risk of disease progression in IgA nephropathy [11][12]. However, hematuria is not a perfect measure of active inflammation. Blood in the urine can also be caused by infections, stones, or menstrual contamination, and its disappearance does not guarantee that your risk has vanished completely [13]. It is one piece of the puzzle interpreted alongside your protein levels and kidney function.
Blood Pressure Control
Blood pressure is a key modifiable risk factor and a primary treatment target [14]. High blood pressure puts extra physical stress on already inflamed kidney filters. Blood pressure targets are highly individualized based on how they are measured (standardized office versus home readings), your age, and your tolerance. Current guidelines suggest a standardized office systolic blood pressure target of less than 120 mm Hg if tolerated, but you should never change your blood pressure medications or targets without your doctor’s supervision [14].
Measuring the eGFR Slope
Your eGFR is an estimate that can fluctuate due to hydration, acute illnesses, or laboratory variation. Values above 90 are often simply reported as “>90.” Therefore, nephrologists track your eGFR slope—the trend of repeated measurements taken when you are clinically stable over months and years [15]. A steady, steeper decline in eGFR is a warning sign that the disease may be progressing, even if the absolute number is still within the normal range [15][16].
Assessing Overall Risk
Your doctor will use multiple factors to estimate your risk. Validated tools (like the International IgAN Prediction Tool) incorporate your eGFR, blood pressure, and proteinuria, alongside your age, race/ethnicity, medication use, and specific findings from your kidney biopsy (such as the MEST-C score) [17]. No single number determines your outcome.
When to Contact Your Care Team
Not seeing red urine does not mean microscopic hematuria has resolved, but newly visible red or cola-colored urine—especially during a respiratory infection—warrants letting your doctor know. Seek prompt medical evaluation if you experience:
- New or severe swelling (edema) in your legs, face, or abdomen
- A marked, sudden decrease in how much you urinate
- Shortness of breath
- Severe headaches or very high home blood pressure readings
- Symptoms of a urinary tract infection (painful urination, fever)
Common questions in this guide
Can I have IgA nephropathy if my eGFR is normal?
What do blood and protein in the urine mean when eGFR is normal?
Does a kidney biopsy confirm IgA nephropathy?
How is risk monitored when IgA nephropathy has not lowered eGFR?
When should I contact my doctor about IgA nephropathy?
Does normal eGFR mean IgA nephropathy is cured?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Understanding eGFR results
Can IgA nephropathy be present even when my eGFR is in range?
Tracking urine protein
Which urine tests, like UPCR or UACR, will my team use to track protein?
Blood pressure control
What blood pressure target should my team set for my IgA nephropathy?
Related questions
Show more
Get notified when new evidence is published on Immunoglobulin A nephropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
IgA Nephropathy in Adults: A Review.
Stoneman S, Teh JW, O'Shaughnessy MM
JAMA 2026; (335(9)):799-813 doi:10.1001/jama.2025.25020.
PMID: 41587026 - 2
Pathophysiology of IgA Nephropathy.
Al Hussain T, Hussein MH, Al Mana H, Akhtar M
Advances in anatomic pathology 2017; (24(1)):56-62 doi:10.1097/PAP.0000000000000134.
PMID: 27941542 - 3
Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy.
Kusano T, Takano H, Kang D, et al.
Human pathology 2016; (49()):135-44.
PMID: 26826420 - 4
Immune abnormalities in IgA nephropathy.
Gentile M, Sanchez-Russo L, Riella LV, et al.
Clinical kidney journal 2023; (16(7)):1059-1070 doi:10.1093/ckj/sfad025.
PMID: 37398689 - 5
Advances in the treatment of IgA nephropathy with biological agents.
Zhuang Y, Lu H, Li J
Chronic diseases and translational medicine 2024; (10(1)):1-11 doi:10.1002/cdt3.104.
PMID: 38450299 - 6
Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.
Chen J, Liu S, Xu H, et al.
Medical science monitor : international medical journal of experimental and clinical research 2020; (26()):e922839 doi:10.12659/MSM.922839.
PMID: 32822333 - 7
Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin A Nephropathy: A Systematic Literature Review.
Lorenzi M, Ali SN, Cadarette S, et al.
Advances in therapy 2025; (42(10)):4824-4865 doi:10.1007/s12325-025-03331-3.
PMID: 40828351 - 8
The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis.
Yamaguchi Y, Kosugi T, Sasaki T, et al.
Clinical journal of the American Society of Nephrology : CJASN 2026; (21(4)):615-625 doi:10.2215/CJN.0000000952.
PMID: 41385286 - 9
Long-term outcomes of IgA nephropathy in China.
Shen X, Chen P, Liu M, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (40(6)):1137-1146 doi:10.1093/ndt/gfae252.
PMID: 39557651 - 10
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.
Heerspink HJL, Rovin BH, Komers R, et al.
Clinical journal of the American Society of Nephrology : CJASN 2026; (21(4)):578-592 doi:10.2215/CJN.0000000961.
PMID: 41428405 - 11
Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database.
Yano Y, Nagasu H, Kanegae H, et al.
Nephrology (Carlton, Vic.) 2024; (29(2)):65-75 doi:10.1111/nep.14250.
PMID: 37871587 - 12
Systematic Review of Persistent Microscopic Hematuria and Kidney Outcomes in IgAN.
Berti GM, Vetrano D, Tringali E, et al.
Kidney international reports 2026; (11(11)):107038 doi:10.1016/j.ekir.2026.107038.
PMID: 42835070 - 13
Remission of hematuria is associated with a better prognosis in immunoglobulin A nephropathy.
Park GN, Lee M, Kim SM, et al.
Kidney research and clinical practice 2026; (45(5)):702-712 doi:10.23876/j.krcp.25.064.
PMID: 42415614 - 14
Comparison of 24-h Urine Protein, Urine Albumin-to-Creatinine Ratio, and Protein-to-Creatinine Ratio in IgA Nephropathy.
Yu G, Cheng J, Li H, et al.
Frontiers in medicine 2022; (9()):809245 doi:10.3389/fmed.2022.809245.
PMID: 35295594 - 15
Estimated Glomerular Filtration Rate Slope and Kidney Outcomes in IgA Nephropathy.
Sasaki T, Tsuboi N, Koike K, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; doi:10.1093/ndt/gfag089.
PMID: 41990459 - 16
Long-Term Outcomes in IgA Nephropathy.
Pitcher D, Braddon F, Hendry B, et al.
Clinical journal of the American Society of Nephrology : CJASN 2023; (18(6)):727-738 doi:10.2215/CJN.0000000000000135.
PMID: 37055195 - 17
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.
Barbour SJ, Coppo R, Zhang H, et al.
JAMA internal medicine 2019; (179(7)):942-952 doi:10.1001/jamainternmed.2019.0600.
PMID: 30980653
This page is for informational purposes only and does not constitute medical advice. A nephrologist should interpret your urine tests, eGFR, and biopsy results and guide decisions about monitoring or treatment.